NCT00786422 - Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions

Venous ThrombosisDeep Vein Thrombosis

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.

Trial Locations (16)

1090

Vienna

1724

Roodepoort

2132

Johannesburg

2193

Johannesburg

4020

Redcliffe

4032

Debrecen

6850

Worcester

7130

Somerset West

27100

Pavia

58100

Holon

80331

München

7830604

Ashkelon

01323-001

São Paulo

1105 AZ

Amsterdam

0084

Pretoria

0157

Pretoria